Please login to the form below

Not currently logged in
Email:
Password:

Tesaro

This page shows the latest Tesaro news and features for those working in and with pharma, biotech and healthcare.

Analysts lukewarm on GSK’s new cancer acquisition

Analysts lukewarm on GSK’s new cancer acquisition

GlaxoSmithKline’s $5.1bn takeover of Tesaro has led to a downgrade from credit rating agency Moody’s – even though it says the deal provides a “solid strengthening” of its cancer ... reduce its debt – more slowly than expected following the

Latest news

More from news
Approximately 9 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat platform and discovery engine TeneoSeek.

  • Deal Watch February 2017 Deal Watch February 2017

    There has been speculation for several months that oncology company Tesaro may be the target for a large pharma bid and as a result its share price has increased by 570%

  • Deal Watch April 2016 Deal Watch April 2016

    Apart from the 3 deals by Abbvie, there were deals by GSK and Janssen with Zymeworks and Tesaro respectively. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for treatment of prostate cancer.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    350.5. AnaptysBio/ Tesaro. Collaboration, licence. mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics